Current antibiotic treatment with beta lactam do not meet pharmacodynamic targets in pediatric intensive care unit patients
ID
Bron
Verkorte titel
Aandoening
Infectious diseases
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The main objective is to determine the prevalence of target attainment for six frequently used beta-lactam antibiotics in the early phase after start of the therapy in PICU patients. Target attainment for beta-lactam antibiotics is set at 100% of time (T) of the dosing interval in which the unbound (free, ƒ) serum antibiotic concentration remains above the above the epidemiological cut-off (ƒT > MICECOFF).
Achtergrond van het onderzoek
Morbidity and mortality in critically ill patients with infection is a global health problem. Emerging evidence supports the importance of optimized antibiotic exposure in pediatric intensive care unit (PICU) patients, while evidence based antibiotic dosing in PICU patients in clinical practice is limited. Changes in pharmacokinetic (PK) parameters of antibiotics in subpopulations of critically ill patient have been defined in previous studies. However, there are no data from studies assessing whether the issues identified in a controlled research environment correspond to clinical practice. Assessment of pharmacodynamic target attainment is warranted to identify whether clinical outcomes for patients admitted to the PICU can be improved. We propose an exploratory pharmacokinetic and pharmacodynamic (PK/PD) study to analyse whether current antibiotic dosing regimens of frequently used beta lactam antibiotics achieve defined therapeutic target concentrations in PICU patients.
Doel van het onderzoek
Current antibiotic treatment with beta lactam do not meet pharmacodynamic targets in pediatric intensive care unit patients
Onderzoeksopzet
Day 0 till 6: bioanalysis of bloodsamples for drug exposure (primary)
Week 1: data abstraction EPR (secondary)
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• Written informed consent has been obtained from the patient or their legally authorised representative
• Suitable intra-arterial access to facilitate sample collection
• Recruitment within 36 hours after start of antibiotic therapy
• Intravenous antibiotic therapy of the target antibiotic should be aimed for at least 2 days
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• Consent not obtained
• Premature infants
• History of anaphylaxis for the study antibiotics
• Study antibiotic cessation before blood collection
• Prophylactic use of the study antibiotics
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL9326 |
| Ander register | METC EMC : MEC-2021-0173 |